Drugs / aNPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07168603 | Sep 2025 → Dec 2026 expected | intervertebral disk degenerative disorder | ASTEROGENE Biomedical Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aNPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168603 ↗ |
| Action | Restore | “aiming to restore or rebuild healthy tissue through biological means” NCT07168603 ↗ |
| Modality | Cell therapy | “cell therapy” NCT07168603 ↗ |
| Route | Other | “single intradiscal injection” NCT07168603 ↗ |